» Articles » PMID: 15027503

A Quality-adjusted Survival (Q-TWiST) Model for Evaluating Treatments for Advanced Stage Cancer

Overview
Journal J Biopharm Stat
Date 2004 Mar 19
PMID 15027503
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Quality of life is an important component in the evaluation of therapies, especially in advanced cancer. Methods available for the analysis of longitudinal quality-of-life data include linear mixed models (including growth curve models), generalized linear models, generalized estimating equations, and joint modeling of quality of life and the missingness process. Quality-adjusted survival (Q-TWiST) has also been useful to compare treatments. By weighting the durations of health states according to their quality of life, one arrives at a single end point reflecting the duration of survival and the quality of life. We propose methods for incorporating longitudinal quality-of-life data into quality-adjusted survival. We divide follow-up time into two states, "poor" and "good," based on a cut-off applied to observed quality-of-life scores. Disease progression is handled as a separate state. We then use survival analysis methods to estimate the mean duration of each state as well as mean quality-adjusted time. The analysis is repeated by varying the cut-off to illustrate the range of possible results. Finally a single summary analysis is achieved by averaging (possibly with weights) across the cut-offs used. We illustrate the methodology using data from a cancer clincial trial.

Citing Articles

Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance).

Major-Elechi B, Novotny P, Singh J, Bonner J, Dueck A, Sargent D Int J Stat Med Res. 2019; 7(4):137-146.

PMID: 31396297 PMC: 6686677. DOI: 10.6000/1929-6029.2018.07.04.4.


Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.

Beaumont J, Salsman J, Diaz J, Deen K, McCann L, Powles T Cancer. 2016; 122(7):1108-15.

PMID: 27000445 PMC: 4996632. DOI: 10.1002/cncr.29888.


Patient preferences in advanced or recurrent ovarian cancer.

Havrilesky L, Secord A, Ehrisman J, Berchuck A, Valea F, Lee P Cancer. 2014; 120(23):3651-9.

PMID: 25091693 PMC: 4429767. DOI: 10.1002/cncr.28940.


Calibration of quality-adjusted life years for oncology clinical trials.

Sloan J, Sargent D, Novotny P, Decker P, Marks R, Nelson H J Pain Symptom Manage. 2013; 47(6):1091-1099.e3.

PMID: 24246787 PMC: 4193473. DOI: 10.1016/j.jpainsymman.2013.07.016.


Observation as a treatment strategy for advanced renal cell carcinoma-a call for prospective validation.

Fisher R, Pender A, Thillai K, Chowdhury S, Pickering L, Khabra K Front Oncol. 2012; 2:155.

PMID: 23120744 PMC: 3484329. DOI: 10.3389/fonc.2012.00155.